<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of candidemia and invasive candidiasis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of candidemia and invasive candidiasis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of candidemia and invasive candidiasis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jose A Vazquez, MD, FACP, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Candidemia refers to presence of <em>Candida</em> species in the blood. <em>Candida</em> in a blood culture should never be viewed as a contaminant and should prompt evaluation for metastatic infection [<a href="#rid1">1</a>].</p><p>Invasive candidiasis refers to systemic <em>Candida</em> infection, in the presence or absence of candidemia; examples include osteoarticular infection and hepatosplenic candidiasis. Candidemia is the most common manifestation of invasive candidiasis. </p><p>The treatment of systemic candidal infection in adults will be reviewed here. Antifungal susceptibility testing and the treatment of candidemia in neonates and children are discussed separately. (See  <a class="medical medical_review" href="/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a> and  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a> and  <a class="medical medical_review" href="/d/html/6014.html" rel="external">"Candidemia and invasive candidiasis in children: Management"</a>.)</p><p>The epidemiology, pathogenesis, clinical manifestations, and diagnosis of candidemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a>.)</p><p>Forms of invasive candidiasis are described separately. (See  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a> and  <a class="medical medical_review" href="/d/html/2466.html" rel="external">"Candida osteoarticular infections"</a> and  <a class="medical medical_review" href="/d/html/2453.html" rel="external">"Candida infections of the central nervous system"</a>.)</p><p class="headingAnchor" id="H2131202954"><span class="h1">CLINICAL EVALUATION</span><span class="headingEndMark"> — </span>Physicians caring for patients with candidemia should be aware that metastatic foci of infection can occur involving the eye (endophthalmitis), heart (endocarditis), kidney (pyelonephritis), joints, or other sites. The clinical manifestations of each condition are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a> and  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a> and  <a class="medical medical_review" href="/d/html/2466.html" rel="external">"Candida osteoarticular infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of ophthalmologic examination</strong> – We pursue routine ophthalmologic examination for all patients with candidemia to evaluate for endophthalmitis. In neutropenic patients, ophthalmologic examination should be deferred until the first week after neutrophil recovery because findings of choroidal and vitreal infection are minimal in the context of neutropenia. (See  <a class="medical medical_review" href="/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Clinical manifestations'</a>.) </p><p></p><p class="bulletIndent1">We believe the benefits of early diagnosis and appropriate management of <em>Candida </em>endophthalmitis (including administration of a prolonged course of an antifungal agent that achieves adequate intraocular concentration) can be vision-saving. Our approach is in alignment with the Infectious Diseases Society of America (IDSA) <em>Candida</em> guideline panel, which favors routine ophthalmologic examination for all patients with candidemia [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a>.)</p><p></p><p class="bulletIndent1">There is debate among professional groups as to the merit of this approach; in July 2021, the American Academy of Ophthalmology issued a statement favoring routine ophthalmologic examination only for patients with candidemia and either ocular symptoms or inability to report symptoms [<a href="#rid2">2</a>]. The statement cites a systematic review including 38 studies and more than 7400 patients with candidemia (including adults, children, and neonates) who underwent ophthalmologic evaluation. Some of the studies were designed to assess the incidence of eye involvement on routine ophthalmologic examination among patients with candidemia, while others were trials designed to compare various antifungal agents for treatment of candidemia. Endophthalmitis was observed in &lt;1 percent of the cases, but the frequency varied markedly among the various studies. The authors voiced concern that endophthalmitis was over-reported in many of these studies when routine examinations were performed, and that this led to invasive interventions and associated harm [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1">While the incidence of endophthalmitis in patients with candidemia may be low, at least one study suggests that the incidence may be increasing, possibly due to the increased use of echinocandins to treat candidemia (echinocandins do not achieve significant intraocular concentrations) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Endogenous Candida endophthalmitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of echocardiography</strong> – Infective endocarditis (IE) should be suspected in non-neutropenic patients with persistently positive blood cultures (with or without physical stigmata of IE), especially in the setting of predisposing conditions such as prior IE or injection drug use (IDU) [<a href="#rid5">5</a>]. In such cases, echocardiography should be pursued. In one study of 20 patients with <em>Candida</em> IE, 65 percent had a history of IDU and 55 percent had a prior episode of bacterial IE [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a>.)</p><p></p><p class="bulletIndent1">Routine echocardiography is not warranted for patients with candidemia in the absence of the above factors, given the rarity of this complication; in one study that included 187 adults with candidemia who underwent routine echocardiography, IE was diagnosed in 5.9 percent of cases [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a>.)</p><p></p><p class="bulletIndent1">Among neutropenic patients, IE is unusual; such patients typically have positive cultures from a gastrointestinal source and are generally at low risk for endocarditis in the context of relative thrombocytopenia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of abdominal imaging</strong> – Uncommonly, liver and spleen abscesses can occur as a complication of candidemia and should be considered in people with abdominal symptoms, liver enzyme abnormalities, and/or persistent fever; in such cases, computed tomography of the abdomen should be pursued. </p><p></p><p class="bulletIndent1">Hepatosplenic candidiasis (chronic disseminated candidiasis) is a distinct syndrome that is typically recognized after neutrophil recovery and bone marrow engraftment in previously neutropenic patients. This syndrome generally occurs in the context of a breakdown of gastrointestinal tract integrity with associated portal invasion, and usually manifests as fever of unknown etiology without candidemia. (See  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a>.) </p><p></p><p class="headingAnchor" id="H1103689968"><span class="h1">MANAGEMENT APPROACH</span></p><p class="headingAnchor" id="H1659878136"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Management of candidemia consists of early and appropriate antifungal therapy and targeted source control, along with individualized decisions regarding central venous catheter removal (if present) [<a href="#rid8">8</a>]. Catheter removal in the absence of concomitant antifungal therapy is not sufficient for management of candidemia [<a href="#rid1">1</a>]. (See <a class="local">'Initial therapy'</a> below and <a class="local">'Central venous catheter removal'</a> below.) </p><p>Blood cultures should be performed daily or every other day after initiation of antifungal therapy and catheter removal to establish clearance of candidemia. If blood cultures remain positive for several days after initiation of antifungal therapy and catheter removal, then a search for a metastatic focus, such as infective endocarditis or an abscess should be undertaken. (See <a class="local">'Clinical evaluation'</a> above.)</p><p class="headingAnchor" id="H2542385092"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Treatment of candidemia consists of prompt initiation of antifungal therapy [<a href="#rid1">1,9-11</a>]. Antifungal agents include the echinocandins, the azoles, and amphotericin B formulations. (See <a class="local">'Antifungal agents'</a> below.)</p><p>Susceptibility testing for azoles and echinocandins is warranted for all bloodstream and other clinically significant <em>Candida</em> isolates [<a href="#rid1">1</a>]. Specific drug resistance information for the various <em>Candida</em> species is discussed below. Antifungal susceptibility testing is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a>.)</p><p>In general, treatment consists of monotherapy; no benefit for combination therapy has been established. In one trial, which included 219 non-neutropenic patients with candidemia and randomly assigned to treatment with either <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg/day) monotherapy for two weeks or fluconazole (800 mg/day) plus amphotericin B (0.7 mg/kg per day) for the first four to seven days followed by fluconazole monotherapy to complete a two-week course of therapy after the blood cultures had cleared, the overall treatment success rates were similar [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H218866864"><span class="h3">Non-neutropenic patients</span><span class="headingEndMark"> — </span>In non-neutropenic patients with candidemia, we suggest initial therapy with one of the following echinocandins  (<a class="graphic graphic_table graphicRef87676" data-inline-graphics="87676" href="/d/graphic/87676.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">Anidulafungin</a>: 200 mg loading dose, then 100 mg intravenously (IV) daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">Caspofungin</a>: 70 mg loading dose, then 50 mg IV daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">Micafungin</a>: 100 mg IV daily</p><p></p><p>In non-neutropenic patients who are not critically ill and who do not have a fluconazole-resistant organism (such as <em>Candida glabrata</em> or <em>Candida krusei</em>), <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg [12 mg/kg] loading dose on day 1, followed by 400 mg [6 mg/kg] orally or IV daily) can be used as an alternative agent. </p><p><a class="drug drug_general" data-topicid="141155" href="/d/drug information/141155.html" rel="external">Rezafungin</a>, a newer echinocandin that can be administered as a once-weekly infusion (400 mg on day 1, then 200 mg once weekly beginning on day 8 for up to four doses), is an alternative. However, we favor other options that have more published clinical efficacy data and clinical experience [<a href="#rid13">13,14</a>]. The US Food and Drug Administration (FDA) has approved rezafungin for use only in adults 18 years and older who have candidemia and invasive candidiasis and who have limited or no alternative options [<a href="#rid15">15</a>]. Because of its long half-life, rezafungin may be considered in situations in which the patient is medically stable and ready for discharge but has an azole-resistant <em>Candida</em> spp (ie, <em>C. glabrata</em> or <em>C. krusei</em>) for which there is no oral therapy. </p><p>If there is intolerance, limited availability, or resistance to other antifungal agents, lipid formulations of amphotericin B (3 to 5 mg/kg IV daily) are an alternative. </p><p>This approach is supported by several randomized trials demonstrating that the echinocandins are as effective as and better tolerated than an amphotericin B formulation or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid16">16-19</a>]. In one randomized trial including more than 500 patients with invasive candidiasis treated with either <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> or <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (of whom 12 percent were neutropenic), success rates for clinical and microbiologic cure in a modified intent-to-treat analysis were similar (89.6 and 89.5 percent, respectively; difference 0.7 percent, 95% CI -5.3 to 6.7); renal dysfunction was more frequent among those treated with liposomal amphotericin B than micafungin (29.9 versus 10.3 percent), as were adverse events leading to treatment discontinuation (9 versus 4.9 percent) [<a href="#rid17">17</a>]. In a randomized trial that included 245 patients with candidemia who were treated with either <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> or fluconazole (of whom 3 percent were neutropenic), the treatment success rate was higher among those treated with anidulafungin compared with fluconazole (75.6 versus 60.2 percent; difference 15.4, 95% CI 3.9-27.0) [<a href="#rid18">18</a>].</p><p>In addition, several randomized trials have shown that <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is as effective as amphotericin B for treatment of candidemia [<a href="#rid20">20-23</a>]. In a meta-analysis including 15 randomized trials comparing antifungal agents for treatment of invasive candidiasis, there was no difference in mortality between fluconazole and amphotericin B (30 versus 33 percent; relative risk [RR] 0.92; 95% CI, 0.72-1.17); however, there was a higher rate of microbiologic failure in those patients who received fluconazole when compared with amphotericin B (27.4 versus 17.8 percent; RR 1.52, 95% CI 1.12-2.07) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H4103964577"><span class="h3">Neutropenic patients</span><span class="headingEndMark"> — </span>In neutropenic patients with candidemia, we recommend initial therapy with one of the following echinocandins: <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>, or <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>; dosing is as summarized in the table  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. An alternative is a lipid formulation amphotericin B (3 to 5 mg/kg daily), but this regimen has more toxicity and appears to be less effective  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). </p><p><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> or other azoles should not be used as initial therapy in neutropenic patients who require antifungal therapy, given the widespread use of azole prophylaxis in neutropenic patients and the resulting increased prevalence of non-albicans<em> Candida</em> species with reduced susceptibility to fluconazole and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>. Use of fluconazole should be reserved for patients who cannot be treated with other antifungal agents and whose absolute neutrophil count is above 500 cells/microL and rising. In one retrospective study, fluconazole monotherapy for <em>C. glabrata</em> fungemia was associated with worse survival than therapy with an echinocandin or amphotericin B [<a href="#rid25">25</a>].</p><p>No randomized trials have been adequately powered to evaluate the efficacy of antifungal therapy among neutropenic patients with candidemia [<a href="#rid1">1</a>]; available data are derived from small subset analyses of randomized trials, open-label studies, and retrospective studies [<a href="#rid16">16,17,22,26-28</a>]. Based on available data in non-neutropenic patients, the response rates to the echinocandins appear to be similar to or better than response rates to amphotericin B [<a href="#rid18">18</a>]. (See <a class="local">'Non-neutropenic patients'</a> above.)</p><p class="headingAnchor" id="H269740415"><span class="h2">Targeted and step-down therapy</span></p><p class="headingAnchor" id="H855306641"><span class="h3">General principles</span><span class="headingEndMark"> — </span>In general, non-neutropenic and neutropenic patients who are clinically stable, who have <em>Candida</em> isolates that are susceptible to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, and who have negative repeat blood cultures can be transitioned to oral fluconazole five to seven days after the antifungal initiation, assuming the gastrointestinal tract is functional [<a href="#rid1">1</a>]. For most <em>Candida</em> species, fluconazole should be given at a dose of 400 mg (6 mg/kg) orally once daily for step-down therapy [<a href="#rid1">1</a>].</p><p>The approach to targeted therapy of candidemia due to fluconazole-resistant species is discussed below.</p><p class="headingAnchor" id="H730651574"><span class="h3">C. albicans</span><span class="headingEndMark"> — </span>The approach to targeted and step-down therapy for patients with <em>Candida albicans</em> infection is as described above. (See <a class="local">'General principles'</a> above.)</p><p>The incidence of antifungal resistance among <em>C. albicans</em> remains low. Among 90,000 isolates of <em>C. albicans</em> collected from 40 countries between 1997 and 2005, only 1.5 percent were resistant to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid29">29</a>]. More recent studies show resistance to fluconazole ranges between 0.3 and 2 percent [<a href="#rid30">30-32</a>]. </p><p>Individual cases and small series of nonmucosal infections with fluconazole-resistant <em>C. albicans</em> have been reported from tertiary care centers; these usually occur in immunosuppressed patients on chronic <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis [<a href="#rid33">33-35</a>].</p><p>Most <em>C. albicans</em> isolates are susceptible to the echinocandins, although resistance has rarely been reported [<a href="#rid36">36,37</a>]. The vast majority of <em>C. albicans</em> isolates are susceptible to amphotericin B.</p><p class="headingAnchor" id="H2447268936"><span class="h3">C. auris</span><span class="headingEndMark"> — </span>In patients with infections due to <em>Candida auris</em>, we suggest targeted initial treatment with an echinocandin; dosing is summarized in the table  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>) [<a href="#rid38">38,39</a>]. Because <em>C. auris</em> can develop resistance quickly, patients receiving antifungal therapy should be monitored carefully with follow-up surveillance blood cultures [<a href="#rid38">38,39</a>]. If the patient does not respond clinically to an echinocandin or has persistent candidemia for several days, treatment can be switched to a lipid formulation of amphotericin B 5 mg/kg IV daily. Azoles are generally not useful in the management of <em>C. auris</em> infections. Moreover, antifungal susceptibility testing should be done on all <em>C. auris</em> strains and used to guide individual selection of antifungal therapy [<a href="#rid40">40</a>].</p><p><em>C. auris</em> is considered multidrug resistant with intrinsic resistance to agents from several antifungal classes, particularly azoles. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> resistance has been variable (3 to 73 percent), whereas <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a> have displayed better activity [<a href="#rid41">41</a>]. Resistance to amphotericin B has been reported in 13 to 35 percent of isolates. Most <em>C. auris</em> isolates have been found susceptible to all of the echinocandins; however, minimum inhibitory concentrations (MICs) are higher than the MICs seen in <em>C. albicans</em>. Some isolates have had elevated MICs for all three major classes of antifungal agents (azoles, polyenes, and echinocandins) [<a href="#rid42">42-44</a>].</p><p>Susceptibility breakpoints for <em>C. auris</em> have not been established; however, based on susceptibility breakpoints established for other <em>Candida</em> species, most <em>C. auris</em> isolates have been highly resistant to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid39">39,41,42,44-47</a>].<em> </em>Tentative MIC resistance breakpoints are ≥32 mcg/mL for fluconazole, ≥2 mcg/mL for amphotericin B, ≥2 mcg/mL for <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, and ≥4 mcg/mL for <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> and <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> [<a href="#rid39">39,48</a>]. These breakpoints are based on closely related <em>Candida</em> species and expert opinion (particularly for amphotericin B, for which there are no breakpoints for any <em>Candida</em> species).</p><p>Given concerns about resistance and transmission of <em>C. auris</em> in health care facilities, there are special screening recommendations and infection control precautions for patients who are colonized or infected with <em>C. auris</em>. (See  <a class="medical medical_review" href="/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis", section on 'C. auris emergence'</a>.)</p><p>Additional details can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fcandida-auris%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLHR374vXwQk9wN80Ra2%2FCc9na6xnlCZbLgt%2FO1t0A%2BXoC6R%2BWXoFICJGPYFa9tIihw%3D%3D&amp;TOPIC_ID=2430" target="_blank">United States Centers for Disease Control and Prevention website</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcandida-auris-emergence-in-england%2Fcandida-auris-identified-in-england&amp;token=wobDA%2FwFA5QQnqoylCH6pqNtHgnGhx5tDp3%2BzxfnDaaawP8FtHzPpSQdmRKMAhwTfTkxzHEMrPckaS2wAsNhHFzFgQKx7NNXO1zSh%2F09Y%2Bf9YsRH5v9pH%2FST7HDGiuJs&amp;TOPIC_ID=2430" target="_blank">Public Health England website</a>.</p><p class="headingAnchor" id="H3644902953"><span class="h3">C. dubliniensis</span><span class="headingEndMark"> — </span>The approach to targeted and step-down therapy for patients with <em>Candida dubliniensis</em> infection is as described above. (See <a class="local">'General principles'</a> above.)</p><p><em>C. dubliniensis</em> shares many phenotypic traits with <em>C. albicans</em>, and many isolates were previously misidentified as <em>C. albicans</em>. Special techniques must be undertaken in the microbiology laboratory to differentiate between these two species [<a href="#rid49">49</a>]. Most <em>C. dubliniensis</em> isolates are susceptible to azoles, echinocandins, and amphotericin B.</p><p class="headingAnchor" id="H2013105557"><span class="h3">C. glabrata</span><span class="headingEndMark"> — </span>For initial targeted treatment of candidemia due to <em>C. glabrata</em>, an echinocandin is preferred over amphotericin B. For patients with serious infection, we favor continuing treatment with an echinocandin. </p><p>Some studies have shown increased rates of echinocandin resistance among <em>C. glabrata</em> bloodstream isolates [<a href="#rid50">50-53</a>]. Resistance should be suspected in patients who have received echinocandins in the recent past and in patients who develop candidemia while receiving an echinocandin for prophylaxis or empiric therapy (eg, for neutropenic fever); in these situations, an amphotericin B formulation should be used until antifungal susceptibility testing results are available. Amphotericin B has delayed killing kinetics against <em>C. glabrata</em> in vitro [<a href="#rid54">54</a>]; therefore, higher doses of amphotericin B are recommended when treating known <em>C. glabrata</em> infection (1 mg/kg daily of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> or 5 mg/kg daily of lipid-based formulations).</p><p>Patients who were treated initially with an echinocandin or amphotericin B, are clinically stable, and have negative blood cultures can be transitioned to oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> after five to seven days of antifungal therapy. In order to step-down to an azole and to oral therapy, in vitro susceptibility data are required. Management of infections caused by <em>C. glabrata</em> isolates with MICs that are considered to be “susceptible” or “susceptible dose dependent” (implying that higher doses of fluconazole should be used [fluconazole 800 mg (12 mg/kg orally once daily)]) or <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> 200 to 300 mg (3 to 4 mg/kg orally twice daily) should be given. In a retrospective study including 127 patients with candidemia due to <em>C.</em> <em>glabrata, </em>higher doses of fluconazole (average dose ≥400 mg) were found to be an independent predictor of survival (odds ratio [OR] 3.96, 95% CI 1.52-10.42) [<a href="#rid55">55</a>]. While these data do not address step-down therapy, they support use of higher fluconazole doses for treatment of susceptible <em>C. glabrata</em>. </p><p><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> MIC thresholds are higher for <em>C. glabrata</em> than for many other <em>Candida</em> species. The Clinical and Laboratory Standards Institute designates <em>C. glabrata</em> isolates with MICs of 32 mcg/mL as "susceptible dose dependent" but many clinicians would not use fluconazole for step-down treatment of <em>C. glabrata</em> infections with an MIC this high [<a href="#rid56">56</a>]. In such cases, an echinocandin (or amphotericin B) would be continued for the duration of therapy. </p><p>Many <em>C. glabrata</em> isolates are now intrinsically resistant to the azoles, mostly due to changes in drug efflux [<a href="#rid1">1,57</a>]. This type of resistance can sometimes be overcome by using higher doses of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, but in general, this approach is not recommended for candidemias or invasive infections. Cross-resistance between fluconazole and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is also common with <em>C. glabrata</em>. <em>C. glabrata</em> is known to exhibit phenotypic heteroresistance to fluconazole, which has been associated with persistent infection [<a href="#rid58">58</a>]. Furthermore, among the <em>Candida</em> species, voriconazole MICs are highest with <em>C. glabrata</em>. Fluconazole-resistant isolates are generally voriconazole-resistant as well [<a href="#rid50">50,59</a>]. (See  <a class="medical medical_review" href="/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Heteroresistance'</a>.)</p><p>There is concern that some <em>C. glabrata</em> bloodstream isolates with resistance to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> can also become resistant to the echinocandins [<a href="#rid50">50,60-62</a>]. In a study including 1669<em> C. glabrata</em> bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole. In addition, 9.3, 9.3, and 8.0 percent of the isolates were also found to be nonsusceptible to <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, and <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, respectively [<a href="#rid50">50</a>]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were also resistant to one or more of the echinocandins, with associated mutations<em> in FKS1 or FKS2</em> genes. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant<em> C. glabrata</em> isolates tested between 2001 and 2004. This is noteworthy because echinocandins were used sparingly in that time period. Similarly, in a study including 1380 <em>C. glabrata</em> bloodstream isolates collected in the United States between 2008 and 2013, 3 to 4 percent of strains were resistant to all three echinocandins, and approximately one-third of echinocandin-resistant strains were resistant to fluconazole [<a href="#rid60">60</a>]. Nearly all of the isolates with an <em>FKS1</em> or <em>FKS2</em> mutation were resistant to at least one echinocandin.</p><p class="headingAnchor" id="H2121876494"><span class="h3">C. guilliermondii</span><span class="headingEndMark"> — </span>Targeted therapy for patients with <em>Candida guilliermondii</em> should be guided by susceptibility testing. An echinocandin can be used as initial therapy while awaiting susceptibility testing. </p><p>Some <em>C. guilliermondii </em>isolates have reduced susceptibility to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> and others have reduced susceptibility to echinocandins [<a href="#rid63">63,64</a>]. <em>C. guilliermondii</em> isolates may be susceptible to other azoles, such as <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, but often fluconazole-resistant strains are cross-resistant to other azoles as well. However, <em>C. guilliermondii</em> is usually susceptible to amphotericin B.</p><p class="headingAnchor" id="H3801167288"><span class="h3">C. krusei</span><span class="headingEndMark"> — </span>For targeted treatment of candidemia due to <em>C. krusei</em>, an echinocandin is the preferred antifungal agent. In general, most <em>C. krusei</em> isolates are resistant to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> but remain susceptible to the echinocandins [<a href="#rid65">65</a>]; however, rare cases of echinocandin resistance have been reported [<a href="#rid66">66-68</a>].<em> C. krusei</em> isolates can also demonstrate decreased susceptibility to amphotericin B; for this reason, higher doses of amphotericin B are warranted for the treatment of <em>C. krusei </em>infections (5 mg/kg daily of lipid-based formulations). </p><p>For oral step-down therapy of <em>C. krusei</em> infection, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is recommended; <em>C. krusei</em> is intrinsically resistant to <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> due to an altered cytochrome P450 isoenzyme; this resistance cannot be overcome with use of higher drug doses [<a href="#rid69">69</a>]. Voriconazole binds more effectively to the cytochrome P450 isoenzyme in <em>C. krusei</em> than fluconazole, resulting in higher susceptibility rates [<a href="#rid70">70</a>]. Cross-resistance between voriconazole and fluconazole does not occur with <em>C. krusei</em>, as has been described with <em>C. glabrata</em>. </p><p>There are geographic differences in the incidence of voriconazole-resistant <em>C. krusei</em>. In an international surveillance study, which included 326 bloodstream isolates of <em>C. krusei</em>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> resistance was observed in only 7.4 percent of isolates; such resistance was most common among isolates from Latin America and uncommon among isolates from North America and Europe [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H2601600660"><span class="h3">C. lusitaniae</span><span class="headingEndMark"> — </span>The approach to targeted and step-down therapy for patients with <em>Candida lusitaniae</em> infection is as described above. (See <a class="local">'General principles'</a> above.)</p><p><em>C. lusitaniae</em> is unique among <em>Candida</em> species in that it is often resistant to or quickly becomes resistant to polyenes, specifically amphotericin B; however, it is usually susceptible to the azoles and echinocandins [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H3323444470"><span class="h3">C. parapsilosis</span><span class="headingEndMark"> — </span>The approach to targeted and step-down therapy for patients with <em>Candida parapsilosis</em> infection is as described above. (See <a class="local">'General principles'</a> above.)</p><p><em>C. parapsilosis</em> is highly susceptible to most antifungal agents. In a surveillance study including 9371 <em>C. parapsilosis</em> isolates collected between 2001 and 2005, high rates of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> susceptibility (91 to 96 percent) and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> susceptibility (95 to 98 percent) were observed in all geographic regions except Africa and the Middle East (79 and 86 percent susceptible to fluconazole and voriconazole, respectively) [<a href="#rid72">72</a>]. Subsequent surveillance studies have demonstrated fluconazole resistance rates ranging from 2 to 6 percent [<a href="#rid30">30-32</a>].</p><p><em>C. parapsilosis</em> MICs for echinocandins are higher than for other <em>Candida</em> species; however, the clinical implications of these in vitro susceptibility data are uncertain [<a href="#rid57">57,73</a>]. In one review of the data from five different treatment trials of <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> use in patients with invasive candidiasis, the overall (clinical and microbiologic) success rate among patients with <em>C. parapsilosis</em> (74 percent) was similar to patients with invasive candidiasis caused by other <em>Candida</em> species [<a href="#rid74">74</a>]. A multicenter, prospective observational study of candidemia due to <em>C. parapsilosis</em> in Spain found no differences in outcomes of patients who were treated with an echinocandin compared with those who were treated with an azole [<a href="#rid75">75</a>]. These results should be interpreted with caution because this was not a randomized trial; however, it is unlikely that such a study will be performed [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H2524809154"><span class="h3">C. tropicalis</span><span class="headingEndMark"> — </span>The approach to targeted and step-down therapy for patients with <em>Candida tropicalis</em> infection is as described above. (See <a class="local">'General principles'</a> above.)</p><p><em>C. tropicalis</em> is usually susceptible to the azoles, amphotericin B, and the echinocandins. However, breakthrough <em>C. tropicalis</em> bloodstream infections with resistance to <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> have been reported rarely in patients with hematologic malignancies [<a href="#rid37">37,77,78</a>]. </p><p class="headingAnchor" id="H299119274"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of therapy for candidemia is uncertain. </p><p>For patients with candidemia in the absence of metastatic complications, a minimum of two weeks of therapy after blood cultures become negative has been used in most clinical trials and is the recommended duration in the 2016 Infectious Diseases Society of America (IDSA) guidelines [<a href="#rid1">1</a>]. In addition, patients should have resolution of symptoms attributable to candidemia <strong>and</strong> resolution of neutropenia (eg, absolute neutrophil count &gt;500 cells/microL and a consistent increasing trend) prior to discontinuation of antifungal therapy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Neutropenia'</a> and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Duration'</a>.)</p><p>For patients with candidemia and metastatic foci of infection (such as endophthalmitis or endocarditis), a longer duration of therapy and consultation with an infectious disease specialist are warranted. Issues related to the management of these conditions are discussed further separately. (See  <a class="medical medical_review" href="/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2466.html" rel="external">"Candida osteoarticular infections"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a>.)</p><p class="headingAnchor" id="H352160364"><span class="h2">Central venous catheter removal</span><span class="headingEndMark"> — </span>We are in agreement with the 2016 IDSA guidelines regarding central venous catheter (CVC) removal in the setting of candidemia [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For non-neutropenic patients with candidemia whose source is presumed to be a CVC, the CVC should be removed as early as possible. Of course, the timeframe should be individualized for each patient. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For neutropenic patients with candidemia, the risk-benefit ratio of CVC removal is less straightforward. Management decisions should be individualized with a careful consideration of the likely source of candidemia (eg, catheter versus gastrointestinal source) and the risk of catheter removal (eg, bleeding):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients with neutropenia in the context of hematologic malignancy, chemotherapy-induced mucositis is common and likely to serve as a gastrointestinal source of candidemia; in such patients, routine catheter removal may not be necessary. In this setting, risks of removal include thrombocytopenia-associated bleeding and risks associated with loss of intravenous access [<a href="#rid1">1,79-82</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients with neutropenia in the absence of gastrointestinal mucositis, the likelihood of catheter-related infection is greater and catheter removal is more important. </p><p></p><p>All patients with candidemia must be treated with antifungal therapy; catheter removal in the absence of concomitant antifungal therapy is not sufficient for the management of candidemia [<a href="#rid1">1</a>]. (See <a class="local">'Initial therapy'</a> above and <a class="local">'Targeted and step-down therapy'</a> above.) </p><p>No randomized trials have assessed the efficacy of CVC removal on the resolution of candidemia [<a href="#rid83">83</a>]. However, limited data suggest that candidemia clears more quickly when CVCs are removed [<a href="#rid84">84,85</a>], and leaving CVCs in place may be associated with increased mortality [<a href="#rid8">8,75,85-88</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a quantitative review of data from seven randomized trials of candidemia and invasive candidiasis (mostly in non-neutropenic patients), CVC removal was associated with decreased mortality (OR 0.50, 95% CI 0.35-0.72) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective subgroup analysis of two randomized trials evaluating antifungal therapy in patients with candidemia, early CVC removal (within 24 or 48 hours) did not improve time to candidemia clearance or rates of persistent or recurrent candidemia, but was associated with improved treatment success and survival; however, in multivariate analysis these benefits were not observed [<a href="#rid80">80</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of patients with cancer, a fivefold difference in quantitative cultures taken from the CVC and a peripheral vein was used to define catheter-associated candidemia; using these criteria, patients with noncatheter sources did not benefit from CVC removal [<a href="#rid89">89</a>]. </p><p></p><p>There are multiple limitations to observational studies and subgroup analyses of randomized trials, including unrecognized confounders, treatment bias, lack of standardized criteria for catheter removal or data on time to removal, and lack of statistical power [<a href="#rid90">90,91</a>]. </p><p class="headingAnchor" id="H4117773015"><span class="h1">ROLE OF EMPIRIC ANTIFUNGAL THERAPY</span><span class="headingEndMark"> — </span>In the absence of bloodstream infection or evidence of invasive candidiasis based on deep tissue culture, the approach to empiric antifungal therapy depends on individual clinical circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with neutropenic fever, empiric antifungal therapy is administered routinely given the substantial risk for developing invasive candidiasis. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Addition of an antifungal agent'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For non-neutropenic patients with sepsis, routine administration of antifungal therapy as part of initial management is not routinely warranted. This is discussed further separately. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Choosing a regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For non-neutropenic, critically ill patients with persistent fever or unexplained hypotension despite broad-spectrum antibacterial therapy, the benefit of empiric antifungal therapy is uncertain. Clinical criteria to guide antifungal initiation decisions regarding its use remain poorly defined.</p><p></p><p class="bulletIndent1">In general, we are in agreement with the 2016 Infectious Diseases Society of America (IDSA) guidelines, which state that empiric antifungal therapy should be considered in critically ill patients with persistent, unexplained fever and risk factors for invasive candidiasis [<a href="#rid1">1</a>]. The relevant risk factors include presence of an indwelling central venous catheter, administration of <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a>, need for hemodialysis, trauma or burns, use of broad-spectrum antibiotics, recent surgery (particularly abdominal surgery), positive serum beta-D-glucan assay, and cultures demonstratin<em>g Candida</em> colonization at nonsterile sites. (See  <a class="medical medical_review" href="/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a>.) </p><p></p><p class="bulletIndent1">In such cases, we favor the use of an echinocandin. <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> is an acceptable alternative agent in patients who have not received prior azoles and are known to be colonized with fluconazole-susceptible <em>Candida</em> species.</p><p></p><p class="bulletIndent1">For patients who receive empiric antifungal therapy but do not respond after four to five days and have no evidence of invasive candidiasis (including a negative serum beta-D-glucan assay, which has high negative predictive value), discontinuation of empiric antifungal therapy is reasonable [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Thus far, clinical studies evaluating the role of empiric antifungal therapy for non-neutropenic patients with ongoing signs of infection in the setting of broad-spectrum antimicrobial therapy have not demonstrated substantial benefit. In a randomized trial including 260 non-neutropenic critically ill patients with<em> Candida</em> colonization, multiorgan failure, and intensive care unit-acquired sepsis, empiric treatment with <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> for 14 days did not result in improved infection-free survival at 28 days. However, it did reduce the rate of new fungal infections [<a href="#rid92">92</a>]. Similarly, in a randomized trial including 241 critically ill patients who underwent surgery for intra-abdominal infection and were treated with either micafungin or placebo, no difference in the incidence of invasive candidiasis was observed (11.1 versus 8.9 percent; difference 2.24 percent, 95% CI -5.52 to 10.20) [<a href="#rid93">93</a>]. Some earlier studies in patients who underwent bowel surgery or had bowel perforation demonstrated some benefit of empiric <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> in this setting [<a href="#rid94">94-96</a>]. </p><p></p><p class="headingAnchor" id="H507950658"><span class="h1">ANTIFUNGAL AGENTS</span><span class="headingEndMark"> — </span>The most common antifungal agents used for the treatment of candidemia are echinocandins (<a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>; <a class="drug drug_general" data-topicid="141155" href="/d/drug information/141155.html" rel="external">rezafungin</a> is not commonly used) and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>; these agents are better tolerated than amphotericin B formulations, which are used less often due to their risk of toxicity [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H258724357"><span class="h2">Echinocandins</span><span class="headingEndMark"> — </span>The echinocandins include <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, and <a class="drug drug_general" data-topicid="141155" href="/d/drug information/141155.html" rel="external">rezafungin</a>. Echinocandins are noncompetitive inhibitors of the synthesis of 1,3-beta-D-glucan, which is an integral component of the fungal cell wall [<a href="#rid97">97</a>]. Echinocandins are fungicidal for most <em>Candida</em> species, have favorable toxicity profiles, and are approved for the treatment of candidemia and other forms of invasive candidiasis. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). Adverse effects of echinocandins are generally mild and include fever, thrombophlebitis, headache, and elevated aminotransferases [<a href="#rid98">98</a>]. The pharmacology of the echinocandins is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/13945.html" rel="external">"Pharmacology of echinocandins and other glucan synthesis inhibitors"</a>.)</p><p>The echinocandins are used extensively for candidemia and invasive candidiasis given their broad-spectrum activity against <em>Candida</em> species. The echinocandins are preferred over azoles for the initial treatment of candidemia and invasive candidiasis in the 2016 Infectious Diseases Society of America (IDSA) guidelines for management of candidiasis [<a href="#rid1">1</a>].</p><p>Echinocandin resistance had been observed in only a few individual cases; however, acquired resistance has been increasingly reported, especially in <em>C. glabrata</em>. The highest echinocandin minimum inhibitory concentrations (MICs) are for <em>C. parapsilosis</em> and <em>C. guilliermondii</em>. The mechanism of echinocandin resistance involves mutations in the <em>FKS1</em> or <em>FKS2</em> genes that control the enzyme targeted by the echinocandins [<a href="#rid61">61,62,73,99</a>]. If an isolate demonstrates echinocandin resistance with acquired mutations in <em>FKS</em> gene “hot spots,” it is typically resistant to the entire class; however, exceptions have been reported, specifically in <em>Candida kefyr</em> isolates [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H1561213648"><span class="h2">Azoles</span><span class="headingEndMark"> — </span>Available azoles include <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>. The azoles inhibit the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase [<a href="#rid101">101</a>]. This enzyme is necessary for the conversion of lanosterol to ergosterol, a vital component of the fungal cellular membrane. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). The pharmacology of the azoles is discussed separately. </p><p>Azoles interact with multiple different cytochrome P450 enzymes; alternative antifungal agents, such as echinocandins, may be preferred if patients are taking other medications that utilize P450 pathways. Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. </p><p><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> has an excellent safety profile, is available in intravenous and oral formulations, and is inexpensive because it is generic. Fluconazole is highly bioavailable, making oral dosing appropriate for most patients [<a href="#rid12">12,20-22</a>]. </p><p>Other available azoles include <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>The activity of <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> against <em>Candida</em> species is superior to that of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, with MICs that are a log or more lower than fluconazole [<a href="#rid102">102</a>]. However, cross-resistance between fluconazole and voriconazole has been observed, especially with <em>C. glabrata</em>. Voriconazole has significantly greater in vitro activity against <em>C. krusei</em> isolates compared with fluconazole [<a href="#rid103">103</a>]. In non-neutropenic patients, voriconazole was shown to be noninferior to amphotericin B for treatment of candidemia and was associated with fewer toxicities [<a href="#rid104">104</a>]. However, marginal benefits over fluconazole and increased relative toxicities limit its utility for primary therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a> is approved for oropharyngeal candidiasis but not for systemic candidiasis. It is also approved for use as a prophylactic agent for fungal infections in allogeneic hematopoietic cell transplant recipients with graft-versus-host disease and in patients with prolonged neutropenia due to chemotherapy for hematologic malignancies. Posaconazole has not been studied extensively for candidemia and may be considered to have marginal benefits over <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">Isavuconazole</a> is not approved for the treatment of candidiasis. It is formulated as a prodrug, isavuconazonium, which is quickly broken down to the active agent, isavuconazole. In a randomized trial that included 450 non-neutropenic patients, the endpoint of noninferiority to <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> for candidemia was not reached; caspofungin had a higher success rate [<a href="#rid105">105</a>]. Isavuconazole would be predicted to have only marginal benefits over <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>.</p><p></p><p class="headingAnchor" id="H3924046577"><span class="h2">Amphotericin B</span><span class="headingEndMark"> — </span>Amphotericin B is a polyene antifungal agent that disrupts fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol, which leads to the formation of pores that allow leakage of cellular components. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). Issues related to pharmacology are discussed separately. </p><p><a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> demonstrates rapidly fungicidal in vitro activity against most species of <em>Candida</em>; it was the standard drug for the treatment of candidiasis for decades. It is rarely used anymore given its association with significant nephrotoxicity and its associated infusion-related adverse events. Lipid-based amphotericin B formulations include <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> and <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> and are associated with less toxicity than amphotericin B deoxycholate.</p><p>Amphotericin B formulations are often avoided due to greater toxicity compared with azoles and echinocandins. They remain useful in cases when resistance to the other antifungal classes is suspected or proven.</p><p class="headingAnchor" id="H1355454465"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Untreated, candidemia has a mortality rate of over 60 percent [<a href="#rid106">106</a>]. With treatment, the mortality is approximately 25 to 40 percent [<a href="#rid8">8,91,107</a>]. Treatment delay has been associated with increased mortality [<a href="#rid10">10,11,108</a>]. In a retrospective study including 230 patients with candidemia, the number of days between identification of candidemia and initiation of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> correlated with increased mortality: zero days (15 percent), one day (24 percent), two days (37 percent), and three days (41 percent) [<a href="#rid10">10</a>].</p><p>Neutrophil recovery is tantamount to recovery from candidemia/candidiasis; mortality rates in neutropenic patients with candidemia approach 100 percent [<a href="#rid109">109</a>].</p><p>Among candidemic patients with septic shock, the outcomes are even poorer. In a retrospective study including 224 patients with septic shock and a positive blood culture for <em>Candida</em> spp, 64 percent died [<a href="#rid9">9</a>]. The in-hospital mortality rate among the 142 patients who had adequate source control within 24 hours of onset of septic shock and antifungal therapy administered within 24 hours of onset of septic shock was 53 percent; among the 82 patients for whom these goals were not attained, the mortality rate was 98 percent. On multivariate analysis, both failure to achieve timely source control (adjusted odds ratio [aOR] 77.4, 95% CI 21.5-278.4) and delayed antifungal therapy (aOR 33.8, 95% CI 9.7-118.0) were associated with a high mortality rate.</p><p>Factors associated with increased mortality in several other studies of hospitalized patients with candidemia include higher APACHE II scores, inadequate <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> dosing, infection with an echinocandin-resistant strain of <em>C. glabrata</em>, <em>C. parapsilosis</em>, or <em>C. tropicalis</em>, retention of a central venous catheter, increasing age, and use of immunosuppressive therapy [<a href="#rid8">8,87,110,111</a>]. In intensive care unit (ICU) patients, diabetes mellitus, immunosuppression, and mechanical ventilation were associated with death in one study [<a href="#rid112">112</a>]. Whereas in non-ICU patients, glucocorticoid use at the time of a positive blood culture was associated with increased mortality in a separate study [<a href="#rid87">87</a>].</p><p>Among cancer patients, persistent neutropenia, higher APACHE III score, and visceral dissemination have all been associated with poor prognosis [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H621812861"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Candidemia refers to presence of <em>Candida</em> species in the blood. Invasive candidiasis refers to systemic <em>Candida</em> infection in the presence or absence of candidemia. Candidemia is the most common manifestation of invasive candidiasis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organ involvement in candidemia</strong> – Physicians caring for patients with candidemia should be aware that metastatic foci of infection can occur involving the eye (endophthalmitis), heart (endocarditis), kidney (pyelonephritis), joints, or other sites. (See <a class="local">'Clinical evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical management of confirmed candidemia</strong> – Management consists of antifungal therapy and individualized decisions regarding central venous catheter removal (if present). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial antifungal therapy</strong> – Selection of antifungal agents depends on the presence or absence of neutropenia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Non-neutropenic patients</strong> – We suggest initial therapy with an echinocandin rather than <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> or amphotericin B  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Non-neutropenic patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neutropenic patients</strong> – We recommend initial therapy with an echinocandin rather than an azole or amphotericin  (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Because of increased risk of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> resistance due to prior azole use, fluconazole and other azoles should not be used as initial therapy in neutropenic patients. (See <a class="local">'Neutropenic patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transition to oral therapy</strong> – In general, patients who are clinically stable, have fluconazole-susceptible isolates, and have negative repeat blood cultures can be transitioned to oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> after five to seven days. A targeted approach to step-down therapy by species is summarized above. (See <a class="local">'Targeted and step-down therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of ophthalmologic examination</strong> – We pursue formal ophthalmologic examination for all patients with candidemia to evaluate for endophthalmitis. (See <a class="local">'Clinical evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Central venous catheter management</strong> – For non-neutropenic patients with candidemia, we suggest central venous catheter (CVC) removal as soon as possible (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For neutropenic patients with candidemia, catheter management should be individualized, with consideration of the likely source of candidemia (eg, catheter versus gastrointestinal source) and the possible risks of catheter removal (eg, bleeding). (See <a class="local">'Central venous catheter removal'</a> above.)</p><p></p><p class="bulletIndent2">Catheter removal in the absence of concomitant antifungal therapy is never sufficient for the management of candidemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring response</strong> – Blood cultures should be performed daily or every other day to establish clearance of candidemia. If blood cultures remain positive for several days after the initiation of appropriate antifungal therapy and catheter removal, a search for a metastatic focus, such as endocarditis or abscess, should be undertaken. Endocarditis should be suspected in non-neutropenic patients with persistently positive blood cultures, especially in the setting of predisposing conditions such as prior endocarditis or injection drug use. (See <a class="local">'Clinical evaluation'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – For non-neutropenic patients in the absence of metastatic complications, we treat for a minimum of two weeks after the blood cultures become negative. Neutropenic patients should have resolution of symptoms attributable to candidemia <strong>and</strong> resolution of neutropenia (eg, absolute neutrophil count &gt;500 cells/microL and rising) prior to discontinuation of antifungal therapy. Patients with metastatic foci of infection (eg, eye, bone, heart, liver, spleen) require a longer duration of therapy. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical management of suspected candidemia</strong> – Because blood cultures are often negative in patients with candidemia, empiric antifungal therapy is indicated in certain situations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutropenic patients</strong> – For patients with neutropenic fever, empiric antifungal therapy is administered routinely given substantial risk for invasive candidiasis. This is discussed in detail separately. (See <a class="local">'Role of empiric antifungal therapy'</a> above and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Addition of an antifungal agent'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-neutropenic patients</strong> – For critically ill patients with persistent fever or unexplained hypotension despite broad-spectrum antibacterial therapy, the benefit of empiric antifungal therapy is uncertain and the decision should be individualized and based on clinical assessment, surrogate markers (eg, serum beta-D-glucan), and culture data demonstrating <em>Candida</em> colonization at nonsterile sites. (See <a class="local">'Role of empiric antifungal therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Breazzano MP, Bond JB 3rd, Bearelly S, et al. American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis. Ophthalmology 2022; 129:73.</a></li><li><a class="nounderline abstract_t">Breazzano MP, Day HR Jr, Bloch KC, et al. Utility of Ophthalmologic Screening for Patients With Candida Bloodstream Infections: A Systematic Review. JAMA Ophthalmol 2019; 137:698.</a></li><li><a class="nounderline abstract_t">Hillenbrand M, Mendy A, Patel K, et al. The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine  Eye Exams. Open Forum Infect Dis 2022; 9:ofac045.</a></li><li><a class="nounderline abstract_t">Sankar NP, Thakarar K, Rokas KE. Candida Infective Endocarditis During the Infectious Diseases and Substance Use Disorder Syndemic: A Six-Year Case Series. Open Forum Infect Dis 2020; 7:ofaa142.</a></li><li><a class="nounderline abstract_t">Morelli MK, Veve MP, Lorson W, Shorman MA. Candida spp. infective endocarditis: Characteristics and outcomes of twenty patients with a focus on injection drug use as a predisposing risk factor. Mycoses 2021; 64:181.</a></li><li><a class="nounderline abstract_t">Fernández-Cruz A, Cruz Menárguez M, Muñoz P, et al. The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis 2015; 34:1543.</a></li><li><a class="nounderline abstract_t">Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110.</a></li><li><a class="nounderline abstract_t">Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739.</a></li><li><a class="nounderline abstract_t">Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25.</a></li><li><a class="nounderline abstract_t">Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640.</a></li><li><a class="nounderline abstract_t">Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221.</a></li><li><a class="nounderline abstract_t">Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis 2021; 73:e3647.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023; 401:49.</a></li><li class="breakAll">Rezafungin label. Approved by United States Federal Drug Administration (FDA), 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf (Accessed on August 24, 2023).</li><li><a class="nounderline abstract_t">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a class="nounderline abstract_t">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a class="nounderline abstract_t">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a class="nounderline abstract_t">Shorr AF, Wu C, Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother 2011; 66:375.</a></li><li><a class="nounderline abstract_t">Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325.</a></li><li><a class="nounderline abstract_t">Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337.</a></li><li><a class="nounderline abstract_t">Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964.</a></li><li><a class="nounderline abstract_t">Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24:426.</a></li><li><a class="nounderline abstract_t">Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1011.</a></li><li><a class="nounderline abstract_t">Le A, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole? Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a class="nounderline abstract_t">Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106:466.</a></li><li><a class="nounderline abstract_t">Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101:170.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Moet GJ, Messer SA, et al. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55:561.</a></li><li><a class="nounderline abstract_t">Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55:1352.</a></li><li><a class="nounderline abstract_t">Posteraro B, Spanu T, Fiori B, et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother 2015; 59:3944.</a></li><li><a class="nounderline abstract_t">White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382.</a></li><li><a class="nounderline abstract_t">Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25:908.</a></li><li><a class="nounderline abstract_t">Oxman DA, Chow JK, Frendl G, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65:1460.</a></li><li><a class="nounderline abstract_t">Hernandez S, López-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48:1382.</a></li><li><a class="nounderline abstract_t">Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Recommendations for treatment of Candida auris. https://www.cdc.gov/fungal/diseases/candidiasis/c-auris-treatment.html (Accessed on August 12, 2018).</li><li><a class="nounderline abstract_t">Tsay S, Kallen A, Jackson BR, et al. Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast. Clin Infect Dis 2018; 66:306.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Recommendations for identification of Candida auris. https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html (Accessed on November 16, 2017).</li><li><a class="nounderline abstract_t">Lamoth F, Kontoyiannis DP. The Candida auris Alert: Facts and Perspectives. J Infect Dis 2018; 217:516.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Clinical Alert to U.S. Healthcare Facilities - Global Emergence of Invasive Infections Caused by the Multidrug-Resistant Yeast Candida auris. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html (Accessed on July 08, 2016).</li><li><a class="nounderline abstract_t">Lyman M, Forsberg K, Reuben J, et al. Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities - Texas and the District of Columbia, January-April 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1022.</a></li><li><a class="nounderline abstract_t">Kilburn S, Innes G, Quinn M, et al. Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020. Antimicrob Agents Chemother 2022; 66:e0224221.</a></li><li><a class="nounderline abstract_t">Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis 2017; 64:134.</a></li><li><a class="nounderline abstract_t">Tsay S, Welsh RM, Adams EH, et al. Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017. MMWR Morb Mortal Wkly Rep 2017; 66:514.</a></li><li><a class="nounderline abstract_t">Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a Review of the Literature. Clin Microbiol Rev 2018; 31.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Candida auris. Antifungal Susceptibility Testing and Interpretation. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (Accessed on January 25, 2022).</li><li><a class="nounderline abstract_t">Ells R, Kock JL, Pohl CH. Candida albicans or Candida dubliniensis? Mycoses 2011; 54:1.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52:3783.</a></li><li><a class="nounderline abstract_t">Costa-de-Oliveira S, Marcos Miranda I, Silva RM, et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother 2011; 55:1312.</a></li><li><a class="nounderline abstract_t">Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48:2373.</a></li><li><a class="nounderline abstract_t">Cantón E, Pemán J, Gobernado M, et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48:2477.</a></li><li><a class="nounderline abstract_t">Eschenauer GA, Carver PL, Patel TS, et al. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13:180.</a></li><li><a class="nounderline abstract_t">Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244.</a></li><li><a class="nounderline abstract_t">Ben-Ami R, Zimmerman O, Finn T, et al. Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence. mBio 2016; 7.</a></li><li><a class="nounderline abstract_t">Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44:1740.</a></li><li><a class="nounderline abstract_t">Pham CD, Iqbal N, Bolden CB, et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58:4690.</a></li><li><a class="nounderline abstract_t">Shields RK, Nguyen MH, Press EG, et al. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob Agents Chemother 2015; 59:7465.</a></li><li><a class="nounderline abstract_t">Beyda ND, John J, Kilic A, et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59:819.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44:3551.</a></li><li><a class="nounderline abstract_t">Marcos-Zambrano LJ, Puig-Asensio M, Pérez-García F, et al. Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46:515.</a></li><li><a class="nounderline abstract_t">Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50:2522.</a></li><li><a class="nounderline abstract_t">Pelletier R, Alarie I, Lagacé R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43:559.</a></li><li><a class="nounderline abstract_t">Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51:1876.</a></li><li><a class="nounderline abstract_t">Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645.</a></li><li><a class="nounderline abstract_t">Fukuoka T, Johnston DA, Winslow CA, et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003; 47:1213.</a></li><li><a class="nounderline abstract_t">Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003; 36:e14.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46:842.</a></li><li><a class="nounderline abstract_t">Desnos-Ollivier M, Bretagne S, Lortholary O, et al. Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations. Antimicrob Agents Chemother 2022; 66:e0172521.</a></li><li><a class="nounderline abstract_t">Colombo AL, Ngai AL, Bourque M, et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010; 54:1864.</a></li><li><a class="nounderline abstract_t">Fernández-Ruiz M, Aguado JM, Almirante B, et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 2014; 58:1413.</a></li><li><a class="nounderline abstract_t">Reboli AC. Editorial commentary: Is the debate about treatment of Candida parapsilosis complex infections with echinocandins much ado about nothing? Clin Infect Dis 2014; 58:1422.</a></li><li><a class="nounderline abstract_t">Pasquale T, Tomada JR, Ghannoun M, et al. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 2008; 61:219.</a></li><li><a class="nounderline abstract_t">Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52:4181.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34:591.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51:295.</a></li><li><a class="nounderline abstract_t">Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33:1959.</a></li><li><a class="nounderline abstract_t">Janum S, Afshari A. Central venous catheter (CVC) removal for patients of all ages with candidaemia. Cochrane Database Syst Rev 2016; 7:CD011195.</a></li><li><a class="nounderline abstract_t">Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21:994.</a></li><li><a class="nounderline abstract_t">Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis 2005; 37:111.</a></li><li><a class="nounderline abstract_t">Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429.</a></li><li><a class="nounderline abstract_t">Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967.</a></li><li><a class="nounderline abstract_t">Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571.</a></li><li><a class="nounderline abstract_t">Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38:1119.</a></li><li><a class="nounderline abstract_t">Brass EP, Edwards JE. Should the guidelines for management of central venous catheters in patients with candidemia be changed now? Clin Infect Dis 2010; 51:304.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis 2012; 54:1123.</a></li><li><a class="nounderline abstract_t">Timsit JF, Azoulay E, Schwebel C, et al. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. JAMA 2016; 316:1555.</a></li><li><a class="nounderline abstract_t">Knitsch W, Vincent JL, Utzolino S, et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 2015; 61:1671.</a></li><li><a class="nounderline abstract_t">Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32:2443.</a></li><li><a class="nounderline abstract_t">Shan YS, Sy ED, Wang ST, et al. Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 2006; 30:119.</a></li><li><a class="nounderline abstract_t">Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066.</a></li><li><a class="nounderline abstract_t">Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142.</a></li><li><a class="nounderline abstract_t">Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006; 355:1154.</a></li><li><a class="nounderline abstract_t">Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724.</a></li><li><a class="nounderline abstract_t">Staab JF, Neofytos D, Rhee P, et al. Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr. Antimicrob Agents Chemother 2014; 58:5421.</a></li><li><a class="nounderline abstract_t">Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008; 29:198.</a></li><li><a class="nounderline abstract_t">Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55:194.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003; 41:1440.</a></li><li><a class="nounderline abstract_t">Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1435.</a></li><li><a class="nounderline abstract_t">Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clin Infect Dis 2019; 68:1981.</a></li><li><a class="nounderline abstract_t">Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414.</a></li><li><a class="nounderline abstract_t">Cornely FB, Cornely OA, Salmanton-García J, et al. Attributable mortality of candidemia after introduction of echinocandins. Mycoses 2020; 63:1373.</a></li><li><a class="nounderline abstract_t">Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480.</a></li><li><a class="nounderline abstract_t">Nucci M, Silveira MI, Spector N, et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27:107.</a></li><li><a class="nounderline abstract_t">Wang E, Farmakiotis D, Yang D, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 2015; 70:2362.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634.</a></li><li><a class="nounderline abstract_t">Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37:1612.</a></li></ol></div><div id="topicVersionRevision">Topic 2430 Version 72.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34293405" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998819" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Utility of Ophthalmologic Screening for Patients With Candida Bloodstream Infections: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35355893" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine Eye Exams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32494579" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Candida Infective Endocarditis During the Infectious Diseases and Substance Use Disorder Syndemic: A Six-Year Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073384" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Candida spp. infective endocarditis: Characteristics and outcomes of twenty patients with a focus on injection drug use as a predisposing risk factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25966975" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412055" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423135" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Septic shock attributed to Candida infection: importance of empiric therapy and source control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758414" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127033" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746765" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32955088" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36442484" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36442484" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490683" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of caspofungin and amphotericin B for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482982" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568028" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anidulafungin versus fluconazole for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147825" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935701" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228472" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922787" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007589" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775201" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of invasive candidal infections: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28584138" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806055" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16353208" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757357" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442797" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115790" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893576" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25896705" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564569" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356806" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430790" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15047549" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016020" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Caspofungin-non-susceptible Candida isolates in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016020" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Caspofungin-non-susceptible Candida isolates in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020224" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020224" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29390110" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Candida auris Alert: Facts and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29390110" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Candida auris Alert: Facts and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292928" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities - Texas and the District of Columbia, January-April 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988485" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28520710" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142078" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Candida auris: a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142078" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Candida auris: a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682314" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Candida albicans or Candida dubliniensis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676885" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149621" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421445" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Breakthrough invasive candidiasis in patients on micafungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215097" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Patterns of amphotericin B killing kinetics against seven Candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29581112" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050800" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355336" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Current treatment strategies for disseminated candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486188" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672401" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890592" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392494" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24879785" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021081" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28438935" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077633" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801435" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320498" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325225" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9756770" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mechanism of fluconazole resistance in Candida krusei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654649" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522762" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Candida lusitaniae infections in the era of fluconazole availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199791" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35412354" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231388" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24642553" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24642556" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Editorial commentary: Is the debate about treatment of Candida parapsilosis complex infections with echinocandins much ado about nothing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024953" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Emergence of Candida tropicalis resistant to caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794386" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810600" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Should vascular catheters be removed from all patients with candidemia? An evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578829" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552086" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Predictors of adverse outcome in cancer patients with candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702290" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Revisiting the source of candidemia: skin or gut?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27398809" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Central venous catheter (CVC) removal for patients of all ages with candidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645855" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764202" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503601" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824910" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment-related risk factors for hospital mortality in Candida bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756477" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Candidemia in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095217" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Management of central venous catheters in patients with cancer and candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578828" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Should the guidelines for management of central venous catheters in patients with candidemia be changed now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412062" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The end of an era in defining the optimal treatment of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706483" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26270686" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599149" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369711" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397206" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550704" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Echinocandin antifungal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971721" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Echinocandins for candidemia in adults without neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23487382" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982083" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366001" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Update on azole antifungals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618284" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682127" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243088" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289478" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520786" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885534" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Attributable mortality of candidemia after introduction of echinocandins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427497" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effects of nosocomial candidemia on outcomes of critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675463" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Risk factors for death among cancer patients with fungemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855759" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942393" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19325476" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
